Imatinib Mesylate in Treating Patients With Metastatic Melanoma

NCT00027586 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

22

Enrollment

OTHER

Sponsor class

Conditions

Melanoma
Skin Neoplasms

Interventions

DRUG: Imatinib mesylate (STI571)

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]